November 25, 2022
Intravitreally injected anti-VEGF drugs are undergoing investigation as researchers look for new treatment options.
November 22, 2022
According to the company, the deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.
November 18, 2022
The company noted the updated PDUFA goal date is February 26, 2023. The FDA also reiterated that they do not plan to hold an advisory committee meeting to discuss the application.
According to the company, LBS-008 is an orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt disease and dry age-related macular degeneration.
Delaying the disease can also delay any onset of vision problems, including diabetic retinopathy and diabetic macular edema.
November 17, 2022
According to the company, ROP Check builds upon its pediatric retina screening portfolio, adding digital management (schedule, document, bill, and transfer) for treating patients with retinopathy of prematurity.
November 16, 2022
Artificial intelligence in a primary care and clinic settings increases the likelihood of catching diabetic retinopathy in underinsured patients, resulting in increased successful referrals.
November 15, 2022
Being able to visualize and evaluate the retinal periphery provides a better understanding of the disease status and supports a better treatment decision.
November 07, 2022
OPT-302 in combination with standard-of-care anti-VEGF-A agents shown to improve visual acuity, anatomic endpoints.
In both patients and controls, investigators measured retinal nerve fiber layer thickness, foveal avascular zone area, and vessel density in the superficial capillary plexus, deep capillary plexus, and radial peripapillary capillary plexus.
